MARAVAI LIFESCIENCES HLDGS-A (MRVI)
US56600D1072 - Common Stock
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and...
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to...
Commit To Purchase Maravai LifeSciences Holdings At $5, Earn 15% Using Options
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Healthcare Undervalued Opportunities Poised for Growth: DYAI, INBS, VTAK, RSCI, VERO, MRVI
Small-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 Guidance
Maravai LifeSciences impresses with Q4 2023 revenue of $74.1 million, surpassing estimates. CEO Trey Martin highlights strong execution, cost reductions, and a 28% adjusted EBITDA margin. 2024 revenue guidance of $265-$285 million exceeds expectations.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Maravai LifeSciences (MRVI) Q4 2023 Earnings Call Transcript
MRVI earnings call for the period ending December 31, 2023.
Maravai 2024 revenue guidance propels stock 20% higher
Maravai LifeSciences (MRVI) saw shares rise 18% after projecting higher revenue guidance for 2024, despite a net loss in Q4 2023. Read more here.
Maravai LifeSciences Holdings GAAP EPS of -$0.80 misses by $0.78, revenue of $74.14M beats by $9.8M (NASDAQ:MRVI)
Maravai LifeSciences (MRVI) reports Q4 earnings, with a GAAP EPS miss of $0.78 but beats revenue expectations.
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation...
TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
Nasdaq Stocks Are Taking Center Stage This Week! DYAI, MRVI, SPWR, VTAK, KAVL, INBS
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services...